-$0.40 Earnings Per Share Expected for Syros Pharmaceuticals Inc (NASDAQ:SYRS) This Quarter

Analysts predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce earnings of ($0.40) per share for the current quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.44). Syros Pharmaceuticals posted earnings per share of ($0.47) in the same quarter last year, which indicates a positive year-over-year growth rate of 14.9%. The business is scheduled to announce its next earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.62) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.33). For the next financial year, analysts expect that the business will report earnings of ($1.80) per share, with EPS estimates ranging from ($2.14) to ($1.44). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.06. The firm had revenue of $2.38 million for the quarter, compared to the consensus estimate of $1.72 million. Syros Pharmaceuticals had a negative net margin of 1,950.42% and a negative return on equity of 84.15%.

SYRS has been the subject of a number of recent research reports. ValuEngine raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Piper Sandler lifted their price target on shares of Syros Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, May 29th. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research note on Thursday, March 5th. BidaskClub raised shares of Syros Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $12.88.

Shares of NASDAQ:SYRS traded up $0.64 on Wednesday, reaching $10.67. The company’s stock had a trading volume of 6,099 shares, compared to its average volume of 421,084. Syros Pharmaceuticals has a 52-week low of $4.26 and a 52-week high of $11.93. The company has a market cap of $475.18 million, a P/E ratio of -5.81 and a beta of 1.62. The company has a 50-day simple moving average of $9.52 and a 200 day simple moving average of $7.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 6.35 and a current ratio of 6.35.

In other news, Director Richard A. Young sold 23,960 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $8.75, for a total value of $209,650.00. Following the sale, the director now directly owns 371,141 shares of the company’s stock, valued at approximately $3,247,483.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Srinivas Akkaraju sold 54,972 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.15, for a total transaction of $612,937.80. The disclosure for this sale can be found here. Insiders sold a total of 141,865 shares of company stock worth $1,496,316 over the last ninety days. Insiders own 14.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in SYRS. Portolan Capital Management LLC boosted its holdings in Syros Pharmaceuticals by 56.8% during the first quarter. Portolan Capital Management LLC now owns 512,570 shares of the company’s stock worth $3,040,000 after buying an additional 185,723 shares in the last quarter. Invesco Ltd. purchased a new stake in Syros Pharmaceuticals during the first quarter worth $534,000. Jacobs Levy Equity Management Inc. purchased a new stake in Syros Pharmaceuticals during the fourth quarter worth $312,000. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in Syros Pharmaceuticals by 318.2% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 46,842 shares of the company’s stock worth $278,000 after buying an additional 35,641 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Syros Pharmaceuticals by 30.6% during the fourth quarter. Nuveen Asset Management LLC now owns 140,627 shares of the company’s stock valued at $972,000 after purchasing an additional 32,988 shares in the last quarter. 98.23% of the stock is currently owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: Moving Average (MA)

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.